ストックスクリーナーアプリを入手
1.36
0.74%
0.01
アフターアワーズ：
1.37
0.01
+0.74%
前日終値:
$1.35
開ける：
$1.35
24時間の取引高:
162.01K
Relative Volume:
0.78
時価総額：
$51.20M
収益：
$25.21M
当期純損益:
$-87.87M
株価収益率:
-0.577
EPS:
-2.357
ネットキャッシュフロー:
$-89.47M
1週間 パフォーマンス:
+8.80%
1か月 パフォーマンス:
-9.33%
6か月 パフォーマンス:
-19.53%
1年 パフォーマンス:
-16.05%
1日の値動き範囲:
$1.28
$1.37
1週間の範囲:
$1.25
$1.375
52週間の値動き範囲:
$1.24
$3.95
Metagenomi Therapeutics Inc Stock (MGX) Company Profile
名前
Metagenomi Therapeutics Inc
セクター
電話
(510) 871-4880
住所
5959 HORTON STREET, EMERYVILLE
Compare MGX vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
MGX
Metagenomi Therapeutics Inc
|
1.36 | 50.82M | 25.21M | -87.87M | -89.47M | -2.357 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Metagenomi Therapeutics Inc Stock (MGX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-05-07 | 開始されました | H.C. Wainwright | Buy |
| 2024-05-02 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2024-03-05 | 開始されました | BMO Capital Markets | Outperform |
| 2024-03-05 | 開始されました | Chardan Capital Markets | Buy |
| 2024-03-05 | 開始されました | JP Morgan | Overweight |
| 2024-03-05 | 開始されました | Jefferies | Buy |
| 2024-03-05 | 開始されました | TD Cowen | Outperform |
| 2024-03-05 | 開始されました | Wells Fargo | Overweight |
すべてを表示
Metagenomi Therapeutics Inc (MGX) 最新ニュース
MGX Q1 2026 Earnings: EPS Misses Estimates as Pre-Revenue Biotech Advances PipelineQuarterly Earnings Report - Newser
MGX Q1 2026 Earnings: Missed Expectations as Pre-Revenue Biotech Advances Gene Editing PipelineEarnings Cycle Outlook - Newser
PRN_FinancialWrapper - FinancialContent
Number of shareholders of Metagenomi Therapeutics, Inc. – NASDAQ:MGX - TradingView
Metagenomi Therapeutics (MGX) price target decreased by 10.71% to 8.50 - MSN
Metagenomi Therapeutics, Inc. (NASDAQ:MGX) Just Reported And Analysts Have Been Cutting Their Estimates - Yahoo Finance
Analysts Have Lowered Expectations For Metagenomi Therapeutics, Inc. (NASDAQ:MGX) After Its Latest Results - simplywall.st
Metagenomi Therapeutics (MGX) reports Q1 loss, misses revenue estimates - MSN
Metagenomi Therapeutics (MGX) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Finance
MSN Money - MSN
Metagenomi Highlights Q1 Progress on MGX-001 Gene Therapy - TipRanks
Metagenomi Therapeutics Reports Business Updates and First Quarter 2026 Financial Results - The Manila Times
Metagenomi Therapeutics: Q1 Earnings Snapshot - KVUE
Metagenomi Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
[10-Q] Metagenomi Therapeutics, Inc. Quarterly Earnings Report - Stock Titan
Metagenomi (NASDAQ: MGX) details Q1 2026 loss, cash runway and MGX-001 IND plans - Stock Titan
Metagenomi gene edit for hemophilia A targets 2027 human trials - Stock Titan
MGX Stock Price, Quote & Chart | METAGENOMI THERAPEUTICS INC (NASDAQ:MGX) - ChartMill
Hemophilia Clinical Trial Pipeline Gains Momentum: 50+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight - GlobeNewswire Inc.
SEC Form DEF 14A filed by Metagenomi Therapeutics Inc. - Quantisnow
[DEF 14A] Metagenomi Therapeutics, Inc. Definitive Proxy Statement - Stock Titan
MGX Price Today: Metagenomi Therapeutics, Inc. Stock Price, Quote & Chart | MEXC - MEXC Exchange
Metagenomi Therapeutics (MGX) Stock: Sentiment Analysis (Weakens) 2026-04-22Large Cap Trends - Xã Thanh Hà
MGX Financials: Income Statement, Balance Sheet & Cash Flow | Metagenomi Therapeutics, Inc - Stock Titan
A smaller gene editor cut Atxn2 protein 64% in mice, Metagenomi says - Stock Titan
Did Metagenomi Therapeutics, Inc. Insiders Breach their Fiduciary Duties to Shareholders? - Eastern Progress
Metagenomi reports compact gene editing tool in Nature journal - Investing.com
What is the valuation of Metagenomi Therapeutics (MGX) Stock | Price at $1.39, Up 0.72%Expert Market Insights - Newser
[Form 4] Metagenomi Therapeutics, Inc. Insider Trading Activity - Stock Titan
MGX: Metagenomi Therapeutics, Inc.Detailed Earnings Estimates - Zacks Investment Research
Metagenomi Can’t Ax IPO Investor Suit Over Moderna Partnership - Bloomberg Law News
If You Invested $1,000 in Metagenomi Therapeutics, Inc (MGX) - Stock Titan
Metagenomi Therapeutics Fiscal Results: Q4 Loss of $22.5M, Annual Loss $87.9MNews and Statistics - IndexBox
Metagenomi Therapeutics (MGX) Reports Q4 Loss, Misses Revenue Estimates - Yahoo Finance
Metagenomi Therapeutics: Q4 Earnings Snapshot - kens5.com
Metagenomi Therapeutics Reports Business Updates and Full Year 2025 Financial Results - Bitget
Metagenomi Therapeutics Q4 Earnings Assessment - Benzinga
MGX Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
MGX Technical Analysis & Stock Price Forecast - Intellectia AI
Metagenomi Therapeutics, Inc. to Present at the 46th Annual TD Cowen Healthcare Conference - The Manila Times
Metagenomi Therapeutics, Inc. CEO Jian Irish to Speak at 46th Annual TD Cowen Healthcare Conference - Quiver Quantitative
Gene-editing firm Metagenomi CEO in TD Cowen fireside chat - Stock Titan
MGXMetagenomi Therapeutics, Inc Latest Stock News & Market Updates - Stock Titan
Is Metagenomi Therapeutics (NASDAQ:MGX) In A Good Position To Deliver On Growth Plans? - Yahoo Finance
Head to Head Analysis: Acusphere (OTCMKTS:ACUS) and Metagenomi (NASDAQ:MGX) - Defense World
Xeris Biopharma (NASDAQ:XERS) and Metagenomi (NASDAQ:MGX) Critical Comparison - Defense World
Metagenomi Therapeutics Inc (MGX) 財務データ
収益
当期純利益
現金流量
EPS
Metagenomi Therapeutics Inc (MGX) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Wein Matthew | See Remarks |
Mar 05 '26 |
Sale |
1.60 |
482 |
771 |
114,549 |
| Irish Jian | Chief Executive Officer |
Mar 05 '26 |
Sale |
1.60 |
1,607 |
2,571 |
333,770 |
| Thomas Brian C. | Director |
Dec 05 '25 |
Sale |
1.77 |
3,830 |
6,786 |
2,510,960 |
| Wein Matthew | See Remarks |
Dec 05 '25 |
Sale |
1.77 |
199 |
353 |
115,031 |
| Wapnick Pamela | Chief Financial Officer |
Dec 05 '25 |
Sale |
1.77 |
1,576 |
2,793 |
188,956 |
| Irish Jian | Chief Executive Officer |
Dec 05 '25 |
Sale |
1.77 |
1,602 |
2,839 |
563,839 |
| Thomas Brian C. | Director |
Sep 05 '25 |
Sale |
1.81 |
2,701 |
4,889 |
2,514,790 |
| Wapnick Pamela | Chief Financial Officer |
Sep 05 '25 |
Sale |
1.81 |
1,576 |
2,853 |
70,532 |
| Irish Jian | Chief Executive Officer |
Sep 05 '25 |
Sale |
1.81 |
1,602 |
2,900 |
316,941 |
| Wein Matthew | See Remarks |
Sep 05 '25 |
Sale |
1.81 |
199 |
360 |
19,230 |
0.98%
0.12%
大文字化:
|
ボリューム (24 時間):